Trial reportJournal of the American College of Cardiology2010
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study.
Trial report in Journal of the American College of Cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02880631 (BAROSTIM THERAPY™ In Resistant Hypertension), which is not on this map. Cited by 128 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BAROSTIM THERAPY™ In Resistant Hypertension: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System
Who cites it
128 citing papers in PubMed, 337 citations in OpenAlex.
- Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success.Journal of the American Heart Association · 2018Trial
- Pacemaker-Mediated Programmable Hypertension Control Therapy.Journal of the American Heart Association · 2017Trial
- Lifestyle modification for resistant hypertension: The TRIUMPH randomized clinical trial.American heart journal · 2015Trial
- Interventional Treatment of Arterial Hypertension in The Modern Era: An Updated Review from the Young Investigator Group of the European Society of Hypertension.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Multimodal, device-based therapeutic targeting of the cardiovascular autonomic nervous system.Nature reviews. Cardiology · 2026Review
- Identification of low threshold off-target activation pathways during stimulation of carotid baroreceptor afferents in swine.bioRxiv : the preprint server for biology · 2026Article
- Do stretch sensors expressed by aortic baroreceptors interact with circulating estradiol to mediate baroreflex sensitivity in hypertension?Frontiers in neuroscience · 2026Review
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Engineered Liposomal Delivery ofPharmaceutics · 2025Article
- Bioelectronic Therapeutics: A Revolutionary Medical Practice in Health Care.Bioelectricity · 2025Review
- Low-level neurostimulation of the renal nerves as a potential therapeutic strategy for hypertension treatment.Frontiers in pharmacology · 2025Article
- Clinical trials in neuromodulatory treatment of drug-resistant hypertension and the need for spinal cord stimulation trials: a PRISMA systematic review.Bioelectronic medicine · 2024Review
- Neurocardiac Axis Physiology and Clinical Applications.International journal of cardiology. Heart & vasculature · 2024Review
- Effects of baroreflex activation therapy on cardiac function and morphology.ESC heart failure · 2024Article
- Alleviating Hypertension by Selectively Targeting Angiotensin Receptor-Expressing Vagal Sensory Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Article
- Key challenges in exploring the rat as a preclinical neurostimulation model for aortic baroreflex modulation in hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Mechanisms and treatment of obesity-related hypertension-Part 1: Mechanisms.Clinical kidney journal · 2024Review
- Recent Advancements in Bioelectronic Medicine: A Review.Current drug delivery · 2024Review
- A Review of the Risk Factors and Management of Refractory Hypertension: The Role of Carotid Sinus Stimulation and Renal Nerve Denervation.Journal of community hospital internal medicine perspectives · 2024Review
- Advances in the Pathogenesis and Treatment of Resistant Hypertension.International journal of molecular sciences · 2023Review
68 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients.
backgroundDespite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients.
methodsForty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An external programmer was used to optimize and individualize efficacy.
resultsBaseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile.
conclusionsThe Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.